Mark Quirk News Today

The U.S. Food and Drug Administration (FDA) in early August approved the company and partner Biogen's pill for postpartum depression (PDD), but rejected it as a treatment for clinical depression, which is a much larger market. Sage said the job cuts, which are part of a reorganization plan, will help it launch the drug for women with PDD and also position the company for long-term growth. As part of the reorganization, Sage said its Chief Scientific Officer Al Robichaud will leave the com...